Saad Saffo1, Chengwei Peng2, Ronald Salem3, Tamar Taddei4,5, Anil Nagar4,5. 1. Section of Digestive Diseases, Yale University School of Medicine, 333 Cedar Street, 1080 LMP, New Haven, CT, 06520-8019, USA. saad.saffo@yale.edu. 2. Department of Hematology and Oncology, New York University Grossman School of Medicine, New York, NY, USA. 3. Department of Surgery, Yale University School of Medicine, New Haven, CT, USA. 4. Section of Digestive Diseases, Yale University School of Medicine, 333 Cedar Street, 1080 LMP, New Haven, CT, 06520-8019, USA. 5. West Haven Veteran Affairs Medical Center, West Haven, CT, USA.
Abstract
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related deaths in the USA. Although management strategies have evolved, there are continued controversies about the use of neoadjuvant chemotherapy (NAC) and pretreatment biliary drainage (PBD) in patients with resectable and potentially resectable disease. AIMS: We aimed to characterize the practice trends and outcomes for NAC and PBD. METHODS: A single-center cohort study was performed. Electronic medical records were reviewed between 2011 and 2019, and 140 patients who had pancreaticoduodenectomy for PDAC were included. Diagnosis, treatment, and outcome data were captured. RESULTS: There were no statistically significant temporal trends relating to the use of chemotherapy and PBD. Overall, 41% of patients received NAC and had improved survival, independent of other factors. Of the 71% who received PBD, only 40% had appropriate indications; 30% experienced postprocedure complications, and 34% required reintervention. Factors associated with the application of PBD included preoperative jaundice (OR 70.5, 95% CI 21.4-306.6) and evaluation by non-tertiary therapeutic endoscopists (OR 3.9, 95% CI 1.3-13.6). PBD was associated with a 12-day delay in surgery among those who did not receive NAC (p = 0.005), but there were no differences in surgical complications or mortality. CONCLUSIONS: Our findings suggest that (1) NAC may confer a survival benefit and (2) PBD should be reserved for individuals with jaundice requiring NAC. Implementation of guidelines by North American gastroenterology societies, multidisciplinary treatment models, and delivery of care at high-volume tertiary centers may help optimize management.
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related deaths in the USA. Although management strategies have evolved, there are continued controversies about the use of neoadjuvant chemotherapy (NAC) and pretreatment biliary drainage (PBD) in patients with resectable and potentially resectable disease. AIMS: We aimed to characterize the practice trends and outcomes for NAC and PBD. METHODS: A single-center cohort study was performed. Electronic medical records were reviewed between 2011 and 2019, and 140 patients who had pancreaticoduodenectomy for PDAC were included. Diagnosis, treatment, and outcome data were captured. RESULTS: There were no statistically significant temporal trends relating to the use of chemotherapy and PBD. Overall, 41% of patients received NAC and had improved survival, independent of other factors. Of the 71% who received PBD, only 40% had appropriate indications; 30% experienced postprocedure complications, and 34% required reintervention. Factors associated with the application of PBD included preoperative jaundice (OR 70.5, 95% CI 21.4-306.6) and evaluation by non-tertiary therapeutic endoscopists (OR 3.9, 95% CI 1.3-13.6). PBD was associated with a 12-day delay in surgery among those who did not receive NAC (p = 0.005), but there were no differences in surgical complications or mortality. CONCLUSIONS: Our findings suggest that (1) NAC may confer a survival benefit and (2) PBD should be reserved for individuals with jaundice requiring NAC. Implementation of guidelines by North American gastroenterology societies, multidisciplinary treatment models, and delivery of care at high-volume tertiary centers may help optimize management.
Authors: Klaus Sahora; Vicente Morales-Oyarvide; Cristina Ferrone; Zhi Ven Fong; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-del Castillo Journal: J Hepatobiliary Pancreat Sci Date: 2016-02-23 Impact factor: 7.027
Authors: F Francesco di Mola; Francesca Tavano; R Rita Rago; Antonio De Bonis; M Rosa Valvano; Angelo Andriulli; Pierluigi di Sebastiano Journal: Langenbecks Arch Surg Date: 2014-03-29 Impact factor: 3.445
Authors: Wee Ngu; Michael Jones; Chrisopher P Neal; Ashley R Dennison; Matthew S Metcalfe; Giuseppe Garcea Journal: ANZ J Surg Date: 2012-10-08 Impact factor: 1.872
Authors: John P Neoptolemos; Deborah D Stocken; Claudio Bassi; Paula Ghaneh; David Cunningham; David Goldstein; Robert Padbury; Malcolm J Moore; Steven Gallinger; Christophe Mariette; Moritz N Wente; Jakob R Izbicki; Helmut Friess; Markus M Lerch; Christos Dervenis; Attila Oláh; Giovanni Butturini; Ryuichiro Doi; Pehr A Lind; David Smith; Juan W Valle; Daniel H Palmer; John A Buckels; Joyce Thompson; Colin J McKay; Charlotte L Rawcliffe; Markus W Büchler Journal: JAMA Date: 2010-09-08 Impact factor: 56.272
Authors: Niels A van der Gaag; Erik A J Rauws; Casper H J van Eijck; Marco J Bruno; Erwin van der Harst; Frank J G M Kubben; Josephus J G M Gerritsen; Jan Willem Greve; Michael F Gerhards; Ignace H J T de Hingh; Jean H Klinkenbijl; Chung Y Nio; Steve M M de Castro; Olivier R C Busch; Thomas M van Gulik; Patrick M M Bossuyt; Dirk J Gouma Journal: N Engl J Med Date: 2010-01-14 Impact factor: 91.245